

Idiopathic Hypertension Therapeutic Pipeline Market Review, H2 2016

Idiopathic Hypertension: Consumption, Demand, Sales, Competitor and Forecast 2016 – 2021

PUNE, INDIA, September 26, 2016

/EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development for Idiopathic (Essential) Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic (Essential) Hypertension and features dormant and discontinued projects.



Complete Report @ <https://www.wiseguyreports.com/reports/649785-idiopathic-essential-hypertension-pipeline-review-h2-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Idiopathic (Essential) Hypertension
- The report reviews pipeline therapeutics for Idiopathic (Essential) Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Idiopathic (Essential) Hypertension therapeutics and enlists all their major and minor projects
- The report assesses Idiopathic (Essential) Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Idiopathic (Essential) Hypertension

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/649785-idiopathic-essential-hypertension-pipeline-review-h2-2016>

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Idiopathic (Essential) Hypertension
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Idiopathic (Essential) Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Have any query @ <https://www.wiseguyreports.com/enquiry/649785-idiopathic-essential-hypertension-pipeline-review-h2-2016>

Table of Content

Therapeutics Development	9
Pipeline Products for Idiopathic (Essential) Hypertension - Overview	9
Idiopathic (Essential) Hypertension - Therapeutics under Development by Companies	10
Idiopathic (Essential) Hypertension - Pipeline Products Glance	11
Late Stage Products	11
Clinical Stage Products	12
Early Stage Products	13
Idiopathic (Essential) Hypertension - Products under Development by Companies	14
Idiopathic (Essential) Hypertension - Companies Involved in Therapeutics Development	15
Actelion Ltd	15
Bayer AG	16
Chong Kun Dang Pharmaceutical Corp.	17
Daiichi Sankyo Company, Limited	18
Eli Lilly and Company	19
HanAll Biopharma Co., Ltd.	20
Innopharmax Inc.	21
Lee's Pharmaceutical Holdings Limited	22
PhaseBio Pharmaceuticals, Inc.	23
Quantum Genomics SA	24
Takeda Pharmaceutical Company Limited	25
Idiopathic (Essential) Hypertension - Therapeutics Assessment	26
Assessment by Monotherapy Products	26
Assessment by Combination Products	27
Assessment by Target	28
Assessment by Mechanism of Action	30
Assessment by Route of Administration	32
Assessment by Molecule Type	34
Drug Profiles	36
(amlodipine besylate + azilsartan medoxomil + hydrochlorothiazide) - Drug Profile	36
Product Description	36
Mechanism Of Action	36
R&D Progress	36
(amlodipine besylate + candesartan cilexetil) - Drug Profile	37
Product Description	37
Mechanism Of Action	37
R&D Progress	37
(atorvastatin calcium + losartan potassium) - Drug Profile	39
Product Description	39
Mechanism Of Action	39
R&D Progress	39
(candesartan cilexetil + nifedipine) - Drug Profile	40

[USD&report_id=649785](#) □

Continued...

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)□

Norah Trent

[wiseguyreports](#)

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/346501002>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.